ZGNX
Price:
$26.68
Market Cap:
$0
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a ...[Read more]
Industry
Biotechnology
IPO Date
2010-11-23
Stock Exchange
NASDAQ
Ticker
ZGNX
According to Zogenix, Inc.’s latest financial reports and current stock price. The company's current ROE is -82.90%. This represents a change of 247.50% compared to the average of -23.86% of the last 4 quarters.
The mean historical ROE of Zogenix, Inc. over the last ten years is -121.48%. The current -82.90% ROE has changed -31.76% with respect to the historical average. Over the past ten years (40 quarters), ZGNX's ROE was at its highest in in the March 2013 quarter at 421.44%. The ROE was at its lowest in in the March 2012 quarter at -3702.16%.
Average
-121.48%
Median
-57.18%
Minimum
-438.81%
Maximum
15.53%
Discovering the peaks and valleys of Zogenix, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 622.24%
Maximum Annual ROE = 15.53%
Minimum Annual Increase = -503.53%
Minimum Annual ROE = -438.81%
Year | ROE | Change |
---|---|---|
2021 | -127.07% | 124.34% |
2020 | -56.64% | -66.91% |
2019 | -171.18% | 622.24% |
2018 | -23.70% | -43.65% |
2017 | -42.06% | -27.14% |
2016 | -57.73% | -503.53% |
2015 | 14.31% | -7.91% |
2014 | 15.53% | -103.54% |
2013 | -438.81% | 34.03% |
2012 | -327.41% | -63.66% |
The current ROE of Zogenix, Inc. (ZGNX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-118.30%
5-year avg
-84.13%
10-year avg
-121.48%
Zogenix, Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zogenix, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Zogenix, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Zogenix, Inc.'s ROE?
How is the ROE calculated for Zogenix, Inc. (ZGNX)?
What is the highest ROE for Zogenix, Inc. (ZGNX)?
What is the 3-year average ROE for Zogenix, Inc. (ZGNX)?
What is the 5-year average ROE for Zogenix, Inc. (ZGNX)?
How does the current ROE for Zogenix, Inc. (ZGNX) compare to its historical average?